Clin2
NCT06172660Possibly a fitRecruiting

RSV prevention study for babies in Connecticut

RSV Infection

Treatments studied

Part of Infections clinical trials.

This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3,750 people
Ages
Up to 1 year
Study type
Observational

Who can take part

  • Your baby is 12 months old or younger when they see a doctor for a respiratory illness.
  • Your baby has a respiratory infection that started less than 10 days ago, with symptoms like fever, cough, or trouble breathing.
  • Your baby lives in Connecticut.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04743609Recruiting
Studying RSV illness impact in babies with ear or lung symptoms

This study looks at how RSV (a common virus that can affect breathing) leads to illness in young children who come to the doctor with ear infections and/or breathing symptoms. It may help doctors better understand the “burden” RSV causes in both home/outpatient and hospital settings.

Créteil
NCT07041190Not yet recruiting· Phase 3
RSV Prevention Trial for Pregnant Women and Newborns

This trial tests two ways to protect babies from RSV: a vaccine given to pregnant women, and an antibody shot given to newborns. Both are already approved—this study checks if using them together works better than either alone.

NCT07232706Recruiting· Phase 3
RSV prevention in infants with nirsevimab and maternal vaccine

This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.

La Roche-sur-Yon
NCT06856967Recruiting
Nirsevimab for RSV in infants under 1 year

This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.

Arezzo, Arezzo
NCT07578298Not yet recruiting· Phase 4
RSV immunity study for Aboriginal and Torres Strait Islander babies

This study tests whether giving a special antibody medicine (called RSV-SMA) to babies aged 6–9 months can help prevent respiratory syncytial virus (RSV), a common virus that causes serious breathing problems in young children. Your baby would receive the medicine and be followed to see if it helps protect them.

Darwin, Northern Territory
NCT07615192Recruiting
RSV Vaccination Experiences in Queensland Infants

This study asks parents in Queensland about their infant's RSV (respiratory syncytial virus) vaccination status and experiences. RSV is a common virus that can cause serious breathing problems in babies, and this research helps understand vaccination patterns.

Brisbane, Queensland

Hear when a new RSV Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.